Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
about
Current Chemotherapy and Potential New Targets in Uterine LeiomyosarcomaManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinA Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyA phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma.Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).The role of adjuvant therapy in uterine leiomyosarcomaA review of treatment of uterine leiomyosarcomas.Pharmacological treatment for uterine leiomyosarcomas.Optimal management of uterine leiomyosarcoma.Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma.Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
P2860
Q26767435-130EEF39-82D0-433D-A4AB-CE9BF1811C7BQ28087771-85413592-7C33-4DEB-927C-EDF710D162E9Q30370631-AA913DA4-EE8A-4527-95AE-8A560B731CA5Q30439459-237B9440-4B20-45FA-8124-CD710F9B3351Q33379886-B086474C-0D00-44E9-BB9B-D9184DB828F4Q33386535-1EEED9FE-7A2E-401B-BE10-9198577007F0Q33397625-B199727D-F1BE-4527-A777-426D926B0FF6Q33415973-E812D20E-A370-414C-AB40-0748040E4B0EQ36117059-DFE4031D-2DA7-4118-9419-72FC512C649DQ36295510-A905D28A-33BD-4AC9-82E2-5C88B1CE9BD9Q36811788-00F78F48-73D0-4E09-86A2-5EAAFC83EDC8Q38153648-BEB69A24-6428-45BB-A0D6-2A14E060F3F8Q38270671-35AEE050-4D3A-4878-97EC-034F552BB0B6Q43173702-44956148-4BA1-4AA9-A0E6-265F88162AE8Q52714338-3617061C-B688-443A-97D3-A2DC8C651CF6Q54711421-FCCA21BE-CCBE-4796-92F9-CCAFDB690581
P2860
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@ast
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@en
type
label
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@ast
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@en
prefLabel
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@ast
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@en
P2093
P1476
Phase II trial of topotecan in ...... ecologic Oncology Group Study.
@en
P2093
P304
P356
10.1097/00000421-200008000-00009
P577
2000-08-01T00:00:00Z